KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies
Open Access
- 30 January 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (7), 8373-8388
- https://doi.org/10.18632/oncotarget.7080
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Wei Pan1, 2, Yan Yang1, Hongcheng Zhu1, Youcheng Zhang3, Rongping Zhou3, Xinchen Sun1 1Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P.R. China 2Department of Oncology, The Second Hospital of Nanjing Jiangning, Nanjing, Jiangsu, P.R. China 3Department of Oncology, Nanjing Jiangning Hospital, Nanjing, Jiangsu, P.R. China Correspondence to: Xinchen Sun, e-mail: starrystyle@hotmail.com Keywords: non-small cell lung cancer, KRAS mutation, prognosis, EGFR-TKI, meta-analysis Received: July 30, 2015 Accepted: January 13, 2016 Published: January 30, 2016Keywords
This publication has 66 references indexed in Scilit:
- Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical OutcomePLOS ONE, 2013
- Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung CancerPLOS ONE, 2013
- The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort studyBMJ Open, 2013
- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancerCancer Genetics, 2013
- A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS MutationClinical Cancer Research, 2013
- Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)Journal of Thoracic Oncology, 2012
- Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancerAnnals of Oncology, 2011
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical TrialsClinical Cancer Research, 2009
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005